From: Design of Phase II cancer trials evaluating survival probabilities
Design | ESS (%) | MDA (%) | ETSL (%) | MTSL (%) |
---|---|---|---|---|
Single Stage | 72.0 (100) | 3.00 (100) | 4.00 (100) | 4.00 (100) |
Simon – no interim accrual | 53.2 (74) | 3.38 (112) | 3.63 (91) | 5.38 (134) |
Simon – interim accrual | 67.4 (94) | 3.38 (112) | 3.22 (80) | 4.38 (109) |
Proposed – minimize ETSL | 63.5 (88) | 3.44 (115) | 3.00 (75) | 4.44 (111) |
Proposed – minimize EDA | 62.0 (86) | 3.27 (109) | 3.08 (77) | 4.27 (107) |